#USA #San Diego #Robbins LLP #Geron Corporation #Rytelo

Important Update for Shareholders of Geron Corporation

Robbins LLP has issued a reminder to shareholders of Geron Corporation (NASDAQ: GERN) about a pending class action lawsuit stemming from the alleged manipulation and misinformation regarding the company's product, Rytelo.

Launched as a promising treatment option for blood cancer, Rytelo is Geron’s telomerase inhibitor designed to address a significant medical need. However, the company's optimistic reports on the drug's market performance have faced serious scrutiny. The lawsuit serves as a critical channel for shareholders who have experienced substantial financial losses between June 7, 2024, and February 25, 2025.

Background on the Allegations

The class action lawsuit claims that Geron did not disclose essential factors affecting Rytelo's performance. Investors were allegedly misled about the product’s initial success and potential for growth. The accusations highlighted the company’s failure to adequately address market competition, seasonality effects, and the overall execution in promoting Rytelo's awareness. As a consequence, the drug did not penetrate the market adequately, leaving unmet patient needs unresolved, particularly for first-line patients.

The complaint reached a tipping point when Geron released its financial results on February 26, 2025. The report indicated a stagnation in Rytelo’s growth, attributing it to external factors like competition, seasonality, and insufficient awareness. This announcement led to a dramatic 32.07% decline in the stock price, revealing the stark contrast between Geron’s public messaging and the underlying market reality.

Next Steps for Shareholders

For those affected, there is still an opportunity to join the class action against Geron Corporation. Interested shareholders should note that individuals wishing to serve as lead plaintiffs must file their documentation with the court by May 12, 2025. This role is significant as it involves guiding the lawsuit on behalf of fellow affected investors. However, it’s important to highlight that participation in the class action is not a prerequisite for recovering any potential losses. Shareholders can choose to remain as absent class members if that aligns with their preference for involvement.

Robbins LLP operates on a contingency fee basis, ensuring that there are no legal expenses or fees incurred by shareholders unless a recovery is achieved.

About Robbins LLP

Robbins LLP has established itself as a leader in the arena of shareholder rights litigation, advocating for those who have been adversely affected by corporate malfeasance. Since its inception in 2002, the firm has focused on assisting shareholders in not only recovering their losses but also improving the accountability of corporate executives and governance structures.

For those seeking updates on ongoing class actions involving Geron Corporation, or for alerts regarding corporate misconduct, signing up for the Stock Watch service is highly recommended. This service keeps shareholders informed about developments that could impact their investments.

For inquiries or to learn more about the class action, you can reach out to attorney Aaron Dumas, Jr. via the contact information provided below.

Contact Information

Aaron Dumas, Jr.
Robbins LLP
5060 Shoreham Pl., Ste. 300
San Diego, CA 92122
Email: robotics@robbinsllp.com
Phone: (800) 350-6003
Website: www.robbinsllp.com

In conclusion, shareholders of Geron Corporation are strongly encouraged to seek legal information and support through Robbins LLP. This situation highlights the importance of transparency in corporate communications and the potential repercussions when companies fail to accurately represent their market conditions.